{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:17:27Z","timestamp":1758046647370,"version":"3.44.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T00:00:00Z","timestamp":1619308800000},"content-version":"am","delay-in-days":359,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.pharma.2020.02.004","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T01:57:30Z","timestamp":1581299850000},"page":"230-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Agranulocytoses m\u00e9dicamenteuses idiosyncrasiques\u00a0: analyse de 7\u00a0ans dans un h\u00f4pital universitaire fran\u00e7ais"],"prefix":"10.1016","volume":"78","author":[{"given":"M.","family":"Duwez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Szymanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Carre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mallaret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lepelley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2020.02.004_bib0165","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","article-title":"Systematic review: agranulocytosis induced by nonchemotherapy drugs","volume":"146","author":"Andersohn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharma.2020.02.004_bib0170","first-page":"1327","article-title":"Idiosyncratic drug-induced agranulocytosis","volume":"37","author":"Federici","year":"2008","journal-title":"Pr Med Paris Fr"},{"key":"10.1016\/j.pharma.2020.02.004_bib0175","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ajh.20176","article-title":"Proportion of drug-related serious rare blood dyscrasias: estimates from the Berlin Case-Control Surveillance Study","volume":"77","author":"Andersohn","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pharma.2020.02.004_bib0180","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1080\/14740338.2017.1376645","article-title":"Non-chemotherapy drug-induced neutropenia - an update","volume":"16","author":"Andr\u00e8s","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.pharma.2020.02.004_bib0185","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1517\/14740338.7.4.481","article-title":"Recognition and management of drug-induced blood cytopenias: the example of drug-induced acute neutropenia and agranulocytosis","volume":"7","author":"Andr\u00e8s","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.pharma.2020.02.004_bib0190","series-title":"EMC AKOS encyclop\u00e9die pratique de m\u00e9decine","article-title":"Neutrop\u00e9nies, agranulocytoses","author":"Baumelou","year":"1998"},{"key":"10.1016\/j.pharma.2020.02.004_bib0195","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/MOH.0b013e3282f15fb9","article-title":"Idiosyncratic drug-induced agranulocytosis or acute neutropenia","volume":"15","author":"Andr\u00e8s","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.pharma.2020.02.004_bib0200","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3324\/haematol.2014.110288","article-title":"How we diagnose neutropenia in the adult and elderly patient","volume":"99","author":"Palmblad","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.pharma.2020.02.004_bib0205","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/ehm.11.12","article-title":"Clinical presentation and management of drug-induced agranulocytosis","volume":"4","author":"Andr\u00e8s","year":"2011","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.pharma.2020.02.004_bib0210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2257.2002.00437.x","article-title":"Nonchemotherapy drug-induced agranulocytosis: experience of the Strasbourg teaching hospital (1985\u20132000) and review of the literature","volume":"24","author":"Andr\u00e8s","year":"2002","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.pharma.2020.02.004_bib0215","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/(SICI)1096-8652(199803)57:3<206::AID-AJH4>3.0.CO;2-Z","article-title":"Drug-associated agranulocytosis: 20\u00a0years of reporting in The Netherlands (1974\u20131994)","volume":"57","author":"van der Klauw","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pharma.2020.02.004_bib0220","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/17425255.2015.985649","article-title":"Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis","volume":"11","author":"Johnston","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.pharma.2020.02.004_bib0225","first-page":"257","article-title":"Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting","volume":"33","author":"Benichou","year":"1991","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.1016\/j.pharma.2020.02.004_bib0230","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.revmed.2005.06.008","article-title":"Groupe d\u2019\u00e9tude des agranulocytoses m\u00e9dicamenteuses des h\u00f4pitaux universitaires de Strasbourg","volume":"27","author":"Andr\u00e8s","year":"2006","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.pharma.2020.02.004_bib0235","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/ajh.21433","article-title":"Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management","volume":"84","author":"Tesfa","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pharma.2020.02.004_bib0240","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1517\/14740338.6.3.323","article-title":"Non-chemotherapy drug-induced agranulocytosis","volume":"6","author":"Garbe","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.pharma.2020.02.004_bib0245","first-page":"299","article-title":"Idiosyncratic drug-induced neutropenia & agranulocytosis","volume":"110","author":"Andr\u00e8s","year":"2017","journal-title":"QJM Mon J Assoc Physicians"},{"key":"10.1016\/j.pharma.2020.02.004_bib0250","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/0897190014546115","article-title":"Nonchemotherapy drug-induced neutropenia and agranulocytosis: could medications be the culprit?","volume":"27","author":"Pick","year":"2014","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.pharma.2020.02.004_bib0255","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08104.x","article-title":"The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis","volume":"150","author":"Andr\u00e8s","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharma.2020.02.004_bib0260","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01695866","article-title":"Risk of agranulocytosis and aplastic anemia in relation to history of infectious mononucleosis: a report from the international agranulocytosis and aplastic anemia study","volume":"67","author":"Levy","year":"1993","journal-title":"Ann Hematol"},{"key":"10.1016\/j.pharma.2020.02.004_bib0265","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archinte.165.8.869","article-title":"Population-based drug-induced agranulocytosis","volume":"165","author":"Ib\u00e1\u00f1ez","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharma.2020.02.004_bib0270","first-page":"111","article-title":"Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France","volume":"40","author":"B\u00e9gaud","year":"1985","journal-title":"Therapie"},{"year":"2000","series-title":"Dictionary of pharmacoepidemiology","author":"Begaud","key":"10.1016\/j.pharma.2020.02.004_bib0275"},{"key":"10.1016\/j.pharma.2020.02.004_bib0280","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bcpt.12418","article-title":"Non-chemotherapy-induced agranulocytosis detected by a prospective pharmacovigilance program in a tertiary hospital","volume":"117","author":"Medrano-Casique","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.pharma.2020.02.004_bib0285","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00228-013-1618-1","article-title":"Drug-induced agranulocytosis in the Berlin case-control surveillance study","volume":"70","author":"Huber","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharma.2020.02.004_bib0290","first-page":"50","article-title":"Incidence, etiology and bone marrow characteristics of non-chemotherapy-induced agranulocytosis","volume":"16","author":"Apinantriyo","year":"2011","journal-title":"Hematol Amst Neth"},{"key":"10.1016\/j.pharma.2020.02.004_bib0295","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/0960327115580603","article-title":"Non-chemotherapy drug-induced agranulocytosis in a tertiary hospital","volume":"35","author":"Navarro-Mart\u00ednez","year":"2016","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.pharma.2020.02.004_bib0300","first-page":"181","article-title":"Neutropenia related to valacyclovir and valganciclovir in 2\u00a0renal transplant patients and treatment with granulocyte colony stimulating factor: a case report","volume":"8","author":"Keles","year":"2010","journal-title":"Exp Clin Transplant Off J Middle East Soc Organ Transplant"},{"key":"10.1016\/j.pharma.2020.02.004_bib0305","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1128\/AAC.38.7.1534","article-title":"Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease","volume":"38","author":"Jacobson","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharma.2020.02.004_bib0310","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2165\/11537230-000000000-00000","article-title":"Proton pump inhibitor-induced neutropenia: possible cross-reactivity between omeprazole and pantoprazole","volume":"30","author":"Gouraud","year":"2010","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.pharma.2020.02.004_bib0315","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/ACI.0b013e328355b8d3","article-title":"Hypersensitivity reactions to proton pump inhibitors","volume":"12","author":"Chang","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.pharma.2020.02.004_bib0160","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40268-017-0172-1","article-title":"Antithyroid drug-induced agranulocytosis: state of the art on diagnosis and management","volume":"17","author":"Vicente","year":"2017","journal-title":"Drugs RD"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450920300110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450920300110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:34:52Z","timestamp":1757720092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450920300110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0003450920300110"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2020.02.004","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Agranulocytoses m\u00e9dicamenteuses idiosyncrasiques\u00a0: analyse de 7\u00a0ans dans un h\u00f4pital universitaire fran\u00e7ais","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2020.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}